Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Enbrel DTC Campaign Should Restore Growth In Psoriasis Market, Amgen Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The company had been sponsoring a disease awareness program while working to bring a branded spot back on the air after an FDA warning letter targeted an initial ad.

You may also be interested in...

Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter

Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.

Amgen Enbrel Clears FDA For Psoriasis Supplemental Indication; Detailing Begins Immediately

The company calls on 3,500 dermatologists for its psoriatic arthritis indication; Amgen hopes to increase promotion to 9,000 dermatolgists.

Gottlieb’s Rx For Coronavirus

Study everything together and a scale-up manufacturing after preliminary efficacy results, former FDA commissioners Gottlieb and McClellan and their coauthors recommend in a pair of white papers on how the US should respond to the coronavirus pandemic.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts